What to review
A medicinal-product record or corporate supply-chain disclosure is specific to its subject. Confirm the classification, documents and parties responsible for the intended shipment separately.
Prepare your inquiry
Include the product or sequence, configuration, quantity, destination and required documents. The team can then review the scope and confirm the available information.
Sources and verification scope
Pharmaceutical imports from China, HS 30, 2025 ↗
WITS / UN Comtrade
Source details (original language)
- Scope
- Reported pharmaceutical imports from China, HS chapter 30
- Document section
- United States and European Union rows; trade value 1000 USD
- Limitations
- Do not add EU aggregate to member countries. Not peptide-only trade.
- Claim verification date
- 2026-09-09
Eli Lilly and Company Form 10-K, fiscal year 2025 ↗
SEC · filing by Eli Lilly and Company
Source details (original language)
- Scope
- Lilly reports reliance on China-based suppliers for portions of its supply chain
- Document section
- Manufacturing and supply, p. 21; third-party supply chain risk factors
- Limitations
- Does not identify Bolang, peptide purchases from Bolang, partnership, endorsement or certification.
- Claim verification date
- 2026-09-09
Importing Biological Materials into the United States ↗
U.S. Customs and Border Protection
Source details (original language)
- Scope
- US import requirements depend on material and applicable agencies
- Document section
- Agency requirements and scope
- Limitations
- Research use does not automatically remove applicable requirements; no universal catalog admission claim.
- Claim verification date
- 2026-09-09